Infectious diseases

Cytovale™ Receives Distinguished Abstract Award from AACC for Evaluation of Sepsis Assay

Retrieved on: 
Thursday, December 17, 2020
Health, Medical devices, Infectious diseases, Hospitals, General Health, Clinical trials, Biotechnology, Epidemiology, Infection

In fact, sepsis is the number one cause of death in hospitals1, the leading cause for hospital readmissions and among the most costly2.

Key Points: 
  • In fact, sepsis is the number one cause of death in hospitals1, the leading cause for hospital readmissions and among the most costly2.
  • The abstract from Cytovale presents the diagnostic value of the Cytovale IntelliSep test in a multi-site, prospective cohort of adults presenting to the ED with signs or suspicion of infection.
  • The authors anticipate that the Cytovale IntelliSep test will improve the identification, management and treatment of sepsis, and have indicated that additional multi-site studies are planned.
  • Cytovale is preparing regulatory submissions for the Cytovale system and IntelliSep test; they are not yet commercially available.

AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses

Retrieved on: 
Thursday, December 17, 2020
Health, FDA, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Branches of biology, Clinical medicine, Stem cells, Infectious diseases, Biotechnology, Cell biology, Hematopoietic stem cell transplantation, Transplantation medicine, Virus, Cell therapy, Respiratory tract infection, ALVR106, AlloVir

The clearance of the IND for ALVR106 advances our third program into clinical trials further exploring the power of our proprietary virus-specific T cell therapy platform.

Key Points: 
  • The clearance of the IND for ALVR106 advances our third program into clinical trials further exploring the power of our proprietary virus-specific T cell therapy platform.
  • Respiratory tract infections due to RSV, influenza, PIV, and hMPV are a major public health concern and are detected in up to 40 percent of allogeneic HSCT patients.
  • AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with weakened immune systems.
  • AlloVirs technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy.

iMetabolic Biopharma Corporation Announces Expansion of its Strategic OmniAb Antibody Discovery Partnership with Ligand Pharmaceuticals Accelerating iMetabolic’s iPlatform™ Technology and Pipeline Development

Retrieved on: 
Thursday, December 17, 2020
Health, Infectious diseases, Genetics, Research, Science, Pharmaceutical, Biotechnology, Ligand’s OmniAb® Antibody Discovery Technology Suite, iMetabolic Biopharma Corporation, Ligand Pharmaceuticals

iMetabolic Biopharma Corporation (iMBP) announces expansion of its strategic partnership relationship with Ligand Pharmaceuticals, building on an earlier alliance agreement initiated in 2018, giving access to Ligands OmniAb platform.

Key Points: 
  • iMetabolic Biopharma Corporation (iMBP) announces expansion of its strategic partnership relationship with Ligand Pharmaceuticals, building on an earlier alliance agreement initiated in 2018, giving access to Ligands OmniAb platform.
  • iMBPs iPlatform pipeline expansion is building upon the accelerating progress in development of its primary iMBP-001 asset.
  • The OmniAb antibody discovery platform has helped accelerate our discovery programs by streamlining both cost and time, thus leading to our program expansion and successful development of the iPlatform.
  • iMetabolic Biopharma Corporation (iMBP) is a platform biopharmaceutical company developing safe, effective, and affordable First-In-Class therapeutics using its cornerstone technology, the iPlatform.

Avaya Announces Solutions to Assist With COVID-19 Vaccine Rollout

Retrieved on: 
Thursday, December 17, 2020
Hardware, Semiconductor, Security, Data management, Consumer electronics, Technology, Audio, Video, Infectious diseases, Other Technology, Telecommunications, Software, Networks, VoIP, Internet, Health, Mobile, Wireless, Telecommunications, Vaccination, COVID-19 vaccine, Medical research, Medicine, Avaya, Medical specialties, Vaccine

Avaya (NYSE:AVYA), a global leader in solutions to improve and simplify communications and collaboration, today announced a suite of digital communications solutions to address the unique challenges related to COVID-19 vaccine administration.

Key Points: 
  • Avaya (NYSE:AVYA), a global leader in solutions to improve and simplify communications and collaboration, today announced a suite of digital communications solutions to address the unique challenges related to COVID-19 vaccine administration.
  • These solutions are designed specifically for healthcare providers and government agencies, and can be applied on top of any existing infrastructure to assist with the critical requirements of successful administration of the vaccine.
  • The rapid development of COVID-19 vaccines is a tremendous achievement, but effectively administering the vaccine to the general public is the critical next step to recovering from this pandemic, said Davide Petramala, Director Avaya OneCloud CPaaS, Avaya.
  • Avaya OneCloud solutions can help accelerate community action by removing resource barriers with automated work flows.

COVID Reshapes Traditional Customer Service as Contact Center Traffic Surges and Consumers Voice Frustration  

Retrieved on: 
Thursday, December 17, 2020
Retail, Technology, Consulting, Professional services, General Health, Women, Online Retail, Infectious diseases, Other Retail, MEN, Specialty, Telecommunications, Consumer, Internet, Health, Marketing, Customer service, Business, Brand management, Services marketing, Computer telephony integration, Customer experience, Product management, Call centre, Customer relationship management, Touchpoint

The report also shows consumer acceptance for new technology that can help call center agents and better serve the immediate needs of the customer.

Key Points: 
  • The report also shows consumer acceptance for new technology that can help call center agents and better serve the immediate needs of the customer.
  • The survey shows that 59 percent of consumers are likely to recommend a company based on a positive contact center experience, which is more important now than ever.
  • 1 in 4 consumers did not get their questions solved the first time when reaching out to a call center.
  • With Conversational Service Automation, enterprises can now engage their customers to effectively build loyalty, improve customer experience and realize operational efficiencies.

AHF Milestone: 1.5 Million Lives Now in Care!

Retrieved on: 
Thursday, December 17, 2020
Women, Infectious diseases, Hospitals, MEN, AIDS, Health, Consumer, Pharmaceutical, General Health, AIDS Healthcare Foundation

It is a privilege to report to that AHF has now reached a truly heartwarming new milestone: AHF now has 1,500,000 lives in care across the globe, said Michael Weinstein, AHF president.

Key Points: 
  • It is a privilege to report to that AHF has now reached a truly heartwarming new milestone: AHF now has 1,500,000 lives in care across the globe, said Michael Weinstein, AHF president.
  • At the time, AHF committed to getting one million of those 20 million on treatment by 2020a benchmark AHF reached in October 2018, two years prior to our 2020 goal.
  • 1 million lives in care under AHF reached/celebrated on October 1, 2018
    500,000 lives in care under AHF reached/celebrated on November 13, 2015
    250,000 lives in care under AHF, reached/celebrated on November 27, 2013
    100,000 lives in care under AHF, reached/celebrated on April 15, 2009
    AHF to Roll Out 1.5 Million Lives in Care Billboard Campaign in the U.S. and to Global Sites To mark its 1.5 million patient milestone, AHF is rolling out a new 1.5 Million Lives in Care billboard campaign in six U.S. cities with 21 billboards, starting in Los Angeles (then expanding to Atlanta, Dallas, South Florida and the Northeast).
  • AHF also launched Housing Is A Human Right ( HHR ), the housing advocacy division of AHF to support its work for housing justice across the U.S.

Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result

Retrieved on: 
Thursday, December 17, 2020
Semiconductor, Health, Infectious diseases, Technology, Manufacturing, Other Manufacturing, Hardware, Health, Medicine, Pandemics, Sarbecovirus, Ultraviolet radiation, Atypical pneumonias, Zoonoses, Ultraviolet, Virus, Light-emitting diode, Severe acute respiratory syndrome coronavirus, Coronavirus

The testing shows Violeds is a breakthrough technology that helps prevent the spread of COVID-19 pandemic caused by aerosolized viruses.

Key Points: 
  • The testing shows Violeds is a breakthrough technology that helps prevent the spread of COVID-19 pandemic caused by aerosolized viruses.
  • View the full release here: https://www.businesswire.com/news/home/20201217005466/en/
    Testing report and results for Seoul Viosys UV LED Violeds module by Korea Testing Laboratory (Photo: Business Wire)
    This air conditioning and heating system testing with Violeds module resulted in 99% disinfection of the airborne viruses in a 60m3 room within 30 minutes.
  • The virus used in testing is bacteriophage PhiX174 which is similar in UVC dosage to SARS-CoV-2 (Coronavirus 2).
  • So Seoul Viosys will continue to offer our patented UV LED technology with harmless effects on humans unlike mercury lamps, said an official at Seoul Viosys.

Kaye Introduces the Kaye® Log -80 Vaccine Temperature Logger for Cold Chain Market to Address COVID-19 Vaccine Storage and Transportation Requirements

Retrieved on: 
Thursday, December 17, 2020
Software, Professional services, Data management, Medical devices, Technology, Infectious diseases, Chemicals, Plastics, Transport, Finance, Manufacturing, Logistics, Supply chain management, Health, Pharmaceutical industry, Articles, Packaging, Business, Health sciences, Food safety, Temperature control, Vaccination, Cold chain, Vaccine, Logger, Kaye

With its introduction of the Kaye Log -80 Vaccine Temperature Logger and KayeTrack Cloud Kaye has applied the same quality principles to ensure the validation and safety of the Cold Chain.

Key Points: 
  • With its introduction of the Kaye Log -80 Vaccine Temperature Logger and KayeTrack Cloud Kaye has applied the same quality principles to ensure the validation and safety of the Cold Chain.
  • This NFC Logger with external probe allows the precise recording and monitoring of products that are using Dry Ice pellets for Cold Chain shipment and storage.
  • View the full release here: https://www.businesswire.com/news/home/20201217005380/en/
    Kaye Log -80 Vaccine Temperature Logger (Photo: KAYE)
    Drugs, vaccines, blood and biological materials are extremely sensitive to temperature variations.
  • The Kaye Log -80 Vaccine Temperature Logger is an extension of Kayes Cold Chain solutions.

Protein Ingredient Market Procurement Report | Roadmap to Recovery for Businesses From the Impact of COVID-19 Pandemic | SpendEdge

Retrieved on: 
Thursday, December 17, 2020
Retail, Fitness & Nutrition, Health, Food, Beverage, Occupational safety and health, Health, Articles, Infectious diseases, Coronavirus disease, Zoonoses, Protein, COVID-19 pandemic, Forecasting

The new Protein Ingredient market research report from SpendEdge indicates an incremental growth during the forecast period as the business impact of COVID-19 spreads.

Key Points: 
  • The new Protein Ingredient market research report from SpendEdge indicates an incremental growth during the forecast period as the business impact of COVID-19 spreads.
  • View the full release here: https://www.businesswire.com/news/home/20201217005371/en/
    SpendEdge has announced the release of its Global Protein Ingredient Market Procurement Intelligence Report (Graphic: Business Wire)
    As the markets recover SpendEdge expects the Protein Ingredient market size to grow by USD 16 billion during the period 2020-2024.
  • Get detailed insights on the COVID-19 pandemic crisis and recovery analysis of the Protein Ingredient market.
  • Download free report sample
    Analysis of the cost and volume drivers and supply market forecasts in various regions are offered in this Protein Ingredient research report.

China’s Lianhua Qingwen Capsules Offers an Herbal Therapeutic Solution for the Pandemic

Retrieved on: 
Thursday, December 17, 2020
Alternative medicine, Infectious diseases, Other Health, Health, Pharmaceutical, Pharmaceutical industry, Lianhua, Medication, Coronavirus disease, Health sciences, Health, Natural sciences

Lianhua Qingwen Capsules is a traditional Chinese patent medicine produced by Yiling Pharmaceutical of China.

Key Points: 
  • Lianhua Qingwen Capsules is a traditional Chinese patent medicine produced by Yiling Pharmaceutical of China.
  • Clinical researches have shown that Lianhua Qingwen can effectively inhibit the Novel Coronavirus, and is widely used in the treatment of patients with mild and moderate symptoms.
  • The research has explained the pharmacological basis of the exact efficacy of Lianhua Qingwen in COVID-19 treatment.
  • In view of the outstanding performance of Lianhua Qingwen, media have been very optimistic about the prospect of Lianhua Qingwen and have expected that it will offer an herbal therapeutic solution for the pandemic.